in general , the maillard reaction is a chemical process that appears in most products containing sugars and amino derivatives . by “ sugars ”, we mean all components having hydroxyl and carboxyl functions on the skeleton of the molecule , whether it is simple such as glucose , fructose , etc ., or complex such as polysaccharides . all of these compounds belong to the carbohydrate class . it is a highly complex reaction that is initiated by a reaction between the nitrogen group of the amino substance and the carboxyl function of the sugars by delocalization of the free electrons present on the molecules ( movement of the electrons ) thus promoting attraction between atoms . at the reaction level , the initial step of the maillard reaction occurs as follows : this reaction is therefore an electronic rearrangement at the level of the carboxyl function of the sugar and the nitrogen atom of the amino derivative : the nitrogen atom captures the electrons of the carbon from the sugar by delocalization of the electrons of the c ═ o double bond . the nitrogen atom is then ionized , enabling the sugar to bind to the amino derivative . water is then eliminated , resulting in a new compound . the sugars are generally represented by rcho , a carboxyl function ( cho ) and the substance aminated by h 2 nr ′, an amine function ( nh 2 ). after this first step , ionization and then isomerization reactions occur , promoted by the aqueous medium in which the various molecules are located . finally , cyclization reactions take place , resulting in colored derivatives . the maillard reaction therefore occurs by a mechanism of condensation between an amino derivative and a sugar in an aqueous medium . by “ condensation ”, we mean any chemical mechanism that enables one molecule to bind to another . the greater the heat is , the more advanced the degradation will be , resulting in products colored by cyclization due to dehydration of the molecules ( loss of a water molecule ). thus , according to the molecules present in the medium and the storage conditions , a yellow coloring slowly occurs until a caramel - brown solution is obtained . this reaction is less intense when the sugar is a polyol or a polysaccharide . this is due to the fact that the chaining of the sugar molecules causes steric hindrance thus limiting interaction with the aminated molecules . at the chemical level , glucosamine , which can be of either natural or synthetic origin , is a glucose molecule to which an amino grouping has bonded . consequently , in water without the addition of sugar , this molecule automatically leads to the appearance of a brown color of the solution by the condensation reaction of the different glucosamine molecules together . this appears clearly in an aqueous 7 . 5 % glucosamine solution . after 8 months at 40 ° c ., the solution takes on a caramel hue . to prevent the appearance of coloring over time in glucosamine solutions , preference is given to a “ prodrug ”, n - acetyl - glucosamine . by “ prodrug ”, we mean stable chemical combinations that release the active substance in non - degraded form at the required dose in the body . in the case of n - acetyl - glucosamine , its administration leads to the release of glucosamine and acetic acid , of which only glucosamine has a therapeutic activity . the migration of a hydrogen of the nh group to the sugar molecule as described above thus becomes impossible in the case of n - acetyl - glucosamine : two hydrogen atoms are needed to trigger the maillard reaction . in the patent kr 2001 0029674 , owing to the greater heat stability of n - acetyl - glucosamine , it is used instead of glucosamine in order to obtain a stable composition in the presence of chondroitin sulfate . in this invention , glucosamine is combined with chondroitin sulfate , which has the special property of being a polysaccharide polymer . this molecule consists of a chain of molecules of n - acetyl - glucosamine and glucuronic acid , which is simply an acid carbohydrate . when placed in solution in water in an amount of 6 . 0 % with respect to the total weight of the composition , the solution thus obtained has a coloring that is ten times less intense than that of a pure 7 . 5 % glucosamine solution . this demonstrates the essential action of the acetyl group on the stability of the glucosamine molecule in the presence of other carbohydrates such as glucuronic acid . many patents mention the combination of these two molecules : glucosamine and chondroitin sulfate in an aqueous and pasty medium . however , none refer directly or indirectly to chemical stabilization by any means , of such a combination . aside from blocking the amine function of glucosamine by an acetyl group or the like , resulting in a new molecule or “ prodrug ”, it is possible to stabilize the nh 2 group by a simpler reaction that takes place at the time of production of the solution . indeed , this blocking of the amine function according to the present invention is based on the fact that the nh 2 group in an acid medium undergoes protonation ( appearance of positive charges ) and enables the binding of an anion ( negative charge ) preventing delocalization of the hydrogens during initialization of the maillard reaction described above . this chemical reaction implements carboxylic acids such as citric or oxalic acid , etc . it has the following equations : this blocking has been demonstrated with solutions of chondroitin sulfate and glucosamine with or without the presence of citric acid . three solutions have been produced , each containing 7 . 5 % glucosamine by weight with respect to the total weight of the composition and 6 . 0 % chondroitin sulfate by weight with respect to the total weight of the composition . in two solutions , anhydrous citric acid was added before the introduction of chondroitin sulfate . one of the solutions was heated at 100 ° c . for 10 minutes . after 8 hours of storage at 40 ° c ., the solutions containing citric acid remained colorless , and the solution without citric acid took on a caramel color . the maillard reaction is almost instantaneous between glucosamine and chondroitin sulfate , because the latter has a very high reactivity owing to the free sulfate function so 3 2 − . the delocalization of the electrons of this group is very significant , thus promoting the maillard reaction ; the citrate group ( negative charge ) clearly binds to the protonated amino function of the glucosamine according to the reaction described above , thus blocking the maillard reaction . however , among all of the patents cited above , none mentions chemical stabilization of the glucosamine / chondroitin sulfate solution in an acid medium , in order to block the amino function so as to slow the maillard reaction . in some cases , such as in patents kr 2004 0100009 and u . s . pat . no . 6 , 730 , 331 , the gel developed has an alkaline ph making the combination even more unstable because , aside from the maillard reaction , the glucosamine degrades rapidly beyond a ph of 7 . 0 . similarly , the patents wo 2006 058105 and gb 1091535 protect an ocular preparation with a neutral ph , which is necessary for such an application . the preparation must be preserved in cold conditions before use . the patent us 2004 254142 mentions the use of citric acid in order to counteract the ph of the medium , but without indicating the ph range , or the fact that it is used to stabilize the solution . the patent us 2003 134825 as well as patent us 2003 138543 protect the use of citric acid as a flavor enhancer and buffer solutions for modifying the melting point of the gelling agents used to produce puddings and other pastries . no reference is made to maintaining the chemical stability of the glucosamine / chondroitin sulfate combination . in general , citric acid is widely used in the pharmaceutical , dietetics and food industries for liquid forms as a flavor enhancer , owing either to the acidity that it gives preparations or to the flavor intensification . thus , in many patents protecting the combination of glucosamine / chondroitin sulfate combined with other active principles , citric acid is cited for its role at the gustatory level and not as an agent for chemical stabilization of the preparation . we can thus cite , in this case , the following patents : kr 2001 0018321 wo 2004 004686 wo 2004 002423 us 2033152642 jp 2001 39408 wo 2004 004686 , wo 2004 002423 , us 2003 152642 . these patents protect a process of production of dietetic bars as well as sports drinks . citric acid is used as a flavor enhancer and to adjust the ph of the drinks in the case of effervescent drinks . no mention is made of the addition of citric acid as a chemical stabilizer of the preparation . ie 981006 . this patent protects the incorporation of citric acid in a powder in order to produce a drinkable solution . no reference is made to the use of citric acid as a chemical stabilizer for the glucosamine / chondroitin combination . other patents protect the chondroitin sulfate / glucosamine combination for other applications , such as : transdermal systems , patent us 2005 232980 . citric acid is used to adjust the viscosity of the transdermal preparation and not to chemically stabilize the combination . parenteral injections , patents ca 2446615 and u . s . pat . no . 6 , 476 , 005 . these patents protect the use of malic acid as a detoxifier and citric acid in a buffer solution with sodium chloride in order to adjust the ph of the preparation . however , any person skilled in the art knows that the ph of a parenteral solution must be as close as possible to the ph of the body , i . e . 7 . 0 . consequently , at this value , the glucosamine / chondroitin sulfate combination is not chemically stable . similarly , patents us 2005 282778 and us 2003 229049 protect parenteral solutions for injection in the spinal disks . again , the ph of such solutions is on the order of 7 . 0 . as above , the citric acid and the monosodium and disodium phosphates are used to buffer the medium so as to have a ph compatible with the biological constants of the body , i . e . a ph of 7 . 0 . patents ep 1354590 and tw 235660b protect the glucosamine / trehalose ( sugar ) combination and mention the instability of glucosamine in the presence of sugars . they recommend the use of acids in order to stabilize the medium without setting the ph range , and they tend to prefer a derivative of ascorbic acid . however , this patent does not protect the glucosamine / chondroitin sulfate combination of which the chemical instability is clearly greater than that of glucosamine alone . thus , to obtain liquid or pasty compositions according to the present invention would require substances that confer a ph of between 2 . 0 and 5 . 0 on the medium . by “ carboxylic acid ”, we mean all substances having at least one cooh acid function releasing a hydrogen ( h + ) in the medium . thus , the invention includes acetic acid and derivatives thereof , adipic acid , azelaic acid , butyric acid and derivatives thereof , citramalic acid , citric acid and derivatives thereof , decanoic acid , diglycolic acid , dodecanedioic acid , trans - 2 - dodecene 1 , 12 - dioic acid , formic acid , fumaric acid , gluconic acid , glutaric acid and derivatives thereof , glycolic acid , glyoxylic acid , hexadecanedioic acid , hexadiene - 2 , 4 - dioic acid , hexanoic acid and derivatives thereof , trans - hexene - 3 - dioic acid , lactic acid , lauric acid , levulinic acid , linoleic acid , maleic acid , malic acid , malonic acid , mellitic acid and derivatives thereof , methyl - 3 - crotonic acid , methyl - 3 - glutyric acid , mucic acid , myristic acid , octanoic acid , oenanthic acid , oleic acid , oxalic acid and derivatives thereof , palmitic acid , pelargonic acid , pentadecanoic acid , trans - pentenoic acid , pentynoic acid , pimelic acid , pivalic acid , propionic acid , propyl - 2 - valerianic acid , pyruvic acid , sebacic acid , sorbic acid , stearic acid , suberic acid , succinic acid and derivatives thereof , tartric acid , tetradecanedioic acid , tiglic acid , tridecanoic acid , undecylenic acid , valeric acid and derivatives thereof . by “ derivatives ”, we mean all molecules having the same chemical radical , such as butyric acid , isobutyric acid , etc . these substances can be used alone or in combination so as to have a ph of the medium between 2 . 0 and 5 . 0 . the inhibition of the maillard reaction between glucosamine and chondroitin sulfate is performed in a liquid medium . this reaction is facilitated by the fact that glucosamine is a molecule that is highly soluble in water and in an alcohol medium . depending on the nature of the acid ( s ) used , the solvents that may be used are either water or alcohol or a mixture of the two . the alcohols capable of being used for this inhibition are ethanol , propanol - 1 and isopropanol . the amount of alcohol capable of being used is limited by the presence of chondroitin sulfate , which is insoluble in these solvents . thus , the amount of alcohol capable of being incorporated into the medium is between 0 . 5 % and 75 % by volume with respect to the total volume of the liquid phase implemented for the liquid or pasty compositions . the amount of acid capable of being incorporated into the medium is dependent on the type ( s ) of acid ( s ) implemented and in particular the number of cooh groups capable of releasing h + ions . this amount is determined by the ratio characterizing the number of acid moles used to block 1 mole of glucosamine . this ratio varies from 1 : 0 . 05 to 1 : 1 . 5 and preferably from 1 : 0 . 25 to 1 : 1 , according to whether the inhibition reaction uses one or more acids . over time , according to the other ingredients present in the medium , the ph of the medium may evolve toward basic values capable of causing destabilization of the complex formed . to prevent a change in the ph of the medium , it is possible to introduce buffer solutions . by “ buffer solution ”, we mean a solution that is capable of absorbing acid or basic ph variations according to their compositions , so as to maintain the ph of the medium at between 2 . 0 and 5 . 0 . among the acid buffer solutions based on acid / salt or acid / base combinations or salt alone , the following compositions are included : sodium chloride potassium phthalate glycine and sodium chloride potassium chloride sodium citrate boric acid neutralized by sodium hydroxide ( borax ) monopotassium phosphate ammonium acetate compositions based on succinic acid combined with sodium hydroxide compositions based on lactic acid combined with lactate compositions based on monopotassium phosphate and dipotassium phosphate . the proportion of these various components enables an acid ph of between 2 . 0 and 5 . 0 to be maintained . the inhibition of the maillard reaction is independent of the origin of the glucosamine and the chondroitin sulfate . thus , the glucosamine of the present invention can be obtained either by chemical synthesis from glucose or by extraction from different substrates of animal origin . in the case of an animal source , the glucosamine is extracted by hydrolysis of the chitin obtained from crustacean carapace . other marine sources can be used , such as sea cucumbers and certain types of mussels . this extraction by hydrolysis can also be performed using other compounds such as amino polysaccharide polymers such as glycoproteins and glycosaminoglycans . depending on the mode and the source of extraction , two types of glucosamine are obtained , form α and form β . these two forms are differentiated by their physical properties . form α has a melting point of 88 ° c ., a rotation of + 100 ° and is in crystalline powder form . form β has a melting point of 110 ° c ., a rotation of + 28 ° and is in needle form . the glucosamine , α or β , of the present invention is in the form of salts of hydrochloric acid , glucosamine hydrochloride or sulfuric acid salts , or glucosamine sulfate . with regard to chondroitin , the only possible source is extraction from a substrate of animal origin . owing to its polysaccharide nature , it cannot be obtained by synthesis . the substrates used for extraction consist of bovine ( trachea ), porcine ( skin , bone , etc .) and fish ( shark , skate , etc .) cartilage . the extraction protocol consists of a proteolytic treatment of these various tissues , followed by a separation and purification process . the extraction processes enable a polymer to be obtained with an average molecular weight on the order of 50 , 000 . some processes result in lower molecular weights enabling better assimilation of the product . the chondroitin sulfates used in this invention have a molecular weight capable of ranging from 10 , 000 to 60 , 000 . chondroitin sulfate , as its name indicates , has sulfate groups on the “ n - acetyl - glucosamine ” unit . depending on the position of these sulfate groups , five types of chondroitin sulfate exist : chondroitin 4 - sulfate : chondroitin sulfate a , where r 1 ═ so 3 h and r 2 ═ h chondroitin 6 - sulfate : chondroitin sulfate c , where r 1 ═ h and r 2 ═ so 3 h chondroitin sulfate b , where r 1 ═ so 3 h and r 2 ═ h with a reverse attachment at c 5 ′ chondroitin 4 , 6 - sulfate : chondroitin sulfate e where r 1 ═ so 3 h and r 2 ═ so 3 h chondroitin 2 , 6 - sulfate : chondroitin sulfate d where r 1 ═ h and r 2 ═ so 3 h and a so 3 h group at c 2 of the glucuronic acid . the three main forms are a , b and c , which are differentiated by their rotation : form a : between − 28 ° and − 32 ° form c : between − 12 ° and − 18 ° form b : between − 60 ° and − 70 °. according to the bibliographic data regarding the use of the glucosamine - chondroitin combination in the field of joints , this invention enables protection of liquid compositions for oral and topical administration in which the glucosamine concentration is between 0 . 10 % and 15 % and that of chondroitin sulfate is between 0 . 06 % and 12 % in a single dose , by weight with respect to the final weight of the composition . by “ single dose ”, we mean the packaging that enables the effective amount of active principle to be administered once per day . these same compositions can be in multi - dose form , in which the glucosamine concentrations may vary from 2 . 0 % to 20 . 0 % by weight with respect to the total weight of the composition , and in which the chondroitin sulfate concentration may vary from 1 . 0 % to 15 % by weight with respect to the total weight of the composition . by “ multi - dose ”, we mean liquid preparations intended to be administered a plurality of times over periods of 15 to 30 days , such as syrups . for oral administration , a certain number of ingredients are added in order to make the composition palatable and to ensure that the microbiological cleanliness is preserved . sweeteners , flavor enhancers , flavors , and , to a lesser degree , coloring agents . the inhibition of the maillard reaction between glucosamine and chondroitin sulfate enables classic “ sugar ”- type sweeteners to be introduced into the composition , because all of the amino functions of the active molecules are blocked . natural sweeteners such as saccharose , fructose , glucose , galactose , etc . sweeteners of natural origin : sorbitol , maltitol , xylitol , glycerol , etc . synthetic sweeteners : aspartame , sucralose , saccharine and sodium salts , acesulfame and salts thereof . the concentrations of sweeteners that are natural or of natural origin are between 5 . 0 % and 50 % by weight with respect to the total weight of the composition . in the case of synthetic sweeteners , the concentrations capable of being used vary from 0 . 05 % to 2 . 00 % by weight with respect to the total weight of the composition . as a general rule , any liquid composition intended for oral administration requires the flavor to be enhanced . certain substances enable this objective to be achieved . these are flavor enhancers . in most cases , they are acids . this invention includes citric acid , malic acid , oxalic acid , tartric acid and ascorbic acid , which may or may not be combined with their salts . the concentrations used vary from 0 . 1 % to 10 . 0 % by weight with respect to the total weight of the composition , according to the type of acid used and the desired flavor , acidic or not . all liquid compositions intended for oral administration require the incorporation of a flavor . these flavors can be natural or synthetic . the concentrations used vary according to the type of flavor and the desired flavor intensity . they range from 0 . 1 % to 10 % by weight with respect to the total weight of the composition . in some cases , the stabilized glucosamine / chondroitin combination can be flavored by a “ fruit juice ” base . under these conditions , the concentration of fruit juice may vary from 20 . 0 % to 85 % by weight with respect to the total weight of the composition . by “ fruit juice ” base , we mean any liquid composition of which the proportion of pure fruit extract is greater than 10 %. to facilitate administration of a liquid form , the appearance of the product , inter alia , the coloring , plays a critical role . coloring agents can therefore be added to said liquid compositions . these coloring agents can be natural or synthetic , and their concentration varies , according to the desired appearance , from 0 . 01 % to 10 % by weight with respect to the total weight of the composition . in the case of liquid or pasty compositions , the introduction of preservatives is essential in order to ensure microbiological cleanliness and to maintain the latter over time . this invention includes benzoic acid and salts thereof , sorbic acid and salts thereof , methyl , propyl and ethyl parahydroxybenzoates and salts thereof . for pasty forms for topical use , benzyl alcohol , butylhydroxyanisol , butylhydroxytoluene and propyl , octyl and dodecyl gallate can also be used . the concentrations used vary according to the results of the “ challenge test ” and are between 0 . 05 % and 1 . 0 % by weight with respect to the total weight of the composition . by “ challenge test ”, we mean a test that enables an estimation , on the basis of a predefined dose of preservative , of the evolution or non - evolution of microorganisms incorporated into a liquid composition . the liquid or pasty compositions of this invention can contain other active principles such as anti - inflammatories , plants , minerals , vitamins , organic sulfur derivatives , etc . these products can be solubilized in the solvent of said compositions or placed in suspension or dispersed in the form of an oil phase in the aqueous phase containing the glucosamine / chondroitin sulfate combination . in the case of suspensions , the particle size of the active substances other than chondroitin sulfate and glucosamine is such that no sedimentation should be observed . the particle size of these active substances may vary from one micron ( micronized form ) to 500 μm . the suspension treatment of these particles can be promoted by incorporating a suspension agent in the medium . by “ suspension agent ”, we mean all substances that confer a certain viscosity on the medium , facilitating the homogeneous distribution of particles in the composition . the suspension agents include suspension agents of natural origin such as cellulose and derivatives thereof , starches and modified starches and derivatives thereof , guar gum , xanthan gum and carrageenans . the concentration of these different substances varies according to their nature and the desired viscosity . for pasty oral compositions , the viscosity varies from 100 cps to 20 , 000 cps . for pasty compositions intended for topical administration , the viscosity may vary from 5 , 000 cps to 100 , 000 cps . the concentrations of suspension agent under such conditions range from 0 . 1 % to 5 %. when active principles other than glucosamine and chondroitin are not soluble in the aqueous or alcohol phase , they can be solubilized in an oil or an organic solvent . in this case , the solubilized active principle is dispersed in the aqueous phase and results in the formation of a more or less viscous liquid composition called an emulsion . this emulsion is a “ water - in - oil ” emulsion when the oil phase is greater in volume than the aqueous phase , and an “ oil - in - water ” emulsion when the reverse is observed . such compositions require the use of oily or organic carriers in order to dissolve certain active principles . by “ carriers ”, we mean all liquid substances that enable the active principles dissolved in the latter to be incorporated into the aqueous phase in solubilized form . vegetable oils , hydrogenated vegetable oils , ethoxylated vegetable oils : olive oil , hazelnut oil , coconut oil , castor oil , soybean oil , sesame oil , etc . mineral oils : paraffin , isoparaffin , cycloparaffin oils , silicone oils , isohexadecane , isododecane , and derivatives , etc . natural oils , squalane , hexamethyltetracosane , mono -, di - and triglycerides , etc . synthetic oils : polyisobutene , hydrogenated polyisobutene , etc . and other classic non - toxic lipophilic , hydrophilic and hydro - lipophilic solvents used to produce drug forms : polypropylene , propylene carbonate , dimethyl isosorbide ether , polyoxyethylene glycols ( macrogols ), polyethylene fatty acid esters , propylene glycol fatty acid esters , propylene glycol dicaprylate / dicaprate , glycerol caprylate / caprate , polyoxyethylene / polyoxypropylene glycol fatty acid esters , triacetine , isopropyl myristate , glycofurol , liquid fatty acid esters , ethyl acetate , butanol , propylene glycol acetate , butyl acetate , ethyleneglycol monobutyl ether , ethyl lactate , butyl acetate , diethyleneglycol monoethylic ether , glycerin monooleate , glycerin linoleate , fatty acid and glycerol esters , glycerol and peg fatty acid esters , etc . the proportion of these different carriers is dependent on the solubility of the active principles and may vary from 1 % to 75 % by volume with respect to the total volume of the liquid composition . in some cases , these solvents require the use of surfactants in order to prevent any phase shifts between the two phases . sorbitane esters : polysorbates , spans , tweens , etc . ; polyethoxylated fatty acids : peg - 8 stearate to peg - 100 stearate ; polyethoxylated fatty alcohols : mixture of peg monolaurate ether having 4 to 23 oxyethylene groups on the polyoxyethylene chain , etc . ; glycol esters : methylglycol stearate ; glycerol esters : glycerol monostearate , peg - 75 stearate , glycol and peg 6 - 32 stearate , etc . ; peg esters ; saccharose esters ; fatty alcohol and peg esters : brij ; phenol alkyl and peg ethers ; surfactants having an amide function : copra fatty acid , lauric acid monoethanolamide , etc . myristic acid , lauric acid diethanolamide , etc . lauric acid mono - isopropanolamine . amphoterics : copra alkyldimethyl ammonium betain , fatty acid derivatives with a betaine structure , lauryl - α - iminodipropionic acid and derivatives thereof , lauryl - myristyl - α - aminopropionic acid and derivatives thereof , etc . the amount of these substances , used to promote solubilization or dispersion of active principles may vary from 0 . 1 % to 10 % by weight with respect to the total weight of the oil phase . in the case of certain pasty compositions for topical administration , it is possible to incorporate carriers facilitating the penetration of the active principles . the greater the difficulty of the chondroitin sulfate , being a large molecule , passing the epidermal barrier , the more important these carriers are . among the substances facilitating this transdermal passage are camphor , menthol , dimethylsulfoxide and methylal . the concentrations of these different carriers may range , according to their activity , from 1 % to 50 % by weight with respect to the total weight of the composition . regardless of the type of composition according to the present invention , the protocol for production of the liquid or pasty composition plays an important role in the stability of the end product . indeed , the timing of the incorporation of the different ingredients during the production process may or may not determine the appearance of the brown coloring , characterizing the maillard reaction . the stabilization of these compositions is obtained by chronological solubilization of the glucosamine , then the carboxylic acid , and finally the chondroitin sulfate . it is indeed essential to dissolve the glucosamine first , then to add the acid in the predefined proportions in order to inhibit the reaction between the glucosamine and the chondroitin . the agitation time is dependent on the amounts used and would not be less than 5 minutes for a volume of 100 ml . this mixture can be produced under heat by bringing the solution to 100 ° c . for the entire agitation time . after cooling , or the time mentioned in order for the reaction to take place under cold conditions , the chondroitin sulfate is added . the mixing time is dependent on the amount used . the other ingredients intended to obtain a more or less viscous liquid aqueous composition are added to this phase thus obtained . it can be in the form of a suspension or not , in which , in either case , the ph must be adjusted in order to maintain an acid environment of which the values are between 2 . 0 and 5 . 0 . an oil phase can be added to the aqueous glucosamine / chondroitin sulfate phase , resulting in more or less viscous emulsions of which the ph must absolutely be adjusted to between 2 . 0 and 5 . 0 . such compositions thus have a degradation rate of less than 10 % after 10 months when they are stored at 25 ° c . and 60 % relative humidity .
the invention relates to the field of pharmaceuticals , dietary supplements and food and , more specifically , to the field of dietary supplements intended for the treatment of degradation of cartilage of any origin . the invention relates to liquid or paste compositions based on glucosamin and chondroitin sulphate , intended to provide elements essential for the synthesis and formation of proteoglycans , in which the chondroitin sulphate / glucosamin combination is stabilised with the addition of carboxylic acids such that the ph of the medium is between 2 and 5 and the chemical degradation rate of the active substances is less than 10 % when stored at 25 ° c . and 60 % relative humidity for 10 months for doses of between 300 and 2400 mg chondroitin sulphate and between 500 and 3000 mg glucosamin . the invention is suitable for the treatment of cartilage degradation and , more specifically , arthrosis .